Target Validation Information
TTD ID	T01318
Target Name	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
Type of Target	Successful
Drug Potency against Target	1-hydroxy-2-dodecyl-4(1H)quinolone	Drug Info	IC50 = 4000 nM	[5]
	2-(2-bromo-2-naphthamido)benzoic acid	Drug Info	IC50 = 8400 nM	[1]
	2-(2-naphthamido)benzoic acid	Drug Info	IC50 = 13800 nM	[1]
	2-(3-(3,5-dichlorophenyl)ureido)benzoic acid	Drug Info	IC50 = 700 nM	[7]
	2-[(biphenyl-4-carbonyl)-amino]-benzoic acid	Drug Info	IC50 = 5000 nM	[1]
	3-hydroxy-2-phenylquinoline-4-carboxylic acid	Drug Info	IC50 = 12000 nM	[2]
	BREQUINAR	Drug Info	IC50 = 3 nM	[7]
	Diethyl 2-((biphenyl-3-ylamino)methylene)malonate	Drug Info	Ki = 10000 nM	[3]
	Ethyl 3-(biphenyl-3-ylamino)-2-cyanoacrylate	Drug Info	Ki = 2.45 nM	[3]
	GNF-PF-85	Drug Info	IC50 = 330 nM	[4]
	N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide	Drug Info	Ki = 30 nM	[3]
	N-(4-bromo-2-methylphenyl)-2-naphthamide	Drug Info	Ki = 20 nM	[3]
	N-(Biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide	Drug Info	IC50 = 90 nM	[6]
Action against Disease Model	Atovaquone	Drug Info	The synergistic potential of a range of biguanides, their triazine metabolites, tetracyclines, and pyrimethamine in combination with atovaquone has been assessed. All five biguanides tested interacted synergistically with atovaquone against Plasmodi uM falcipar uM in vitro. All of the other compounds tested were either additive or antagonistic.IC50 on Plasmodi uM falcipar uMin vitro: 0.9nM	[8]
References
REF 1	The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett. 2006 Jan 1;16(1):88-92.
REF 2	Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists. J Med Chem. 2007 Jan 11;50(1):21-39.
REF 3	Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem. 2007 Jan 25;50(2):186-91.
REF 4	Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falcipa... J Med Chem. 2008 Jun 26;51(12):3649-53.
REF 5	Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors. Bioorg Med Chem Lett. 2009 Feb 1;19(3):972-5.
REF 6	Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J Med Chem. 2009 May 14;52(9):2683-93.
REF 7	Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1981-4.
REF 8	Biguanide-atovaquone synergy against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 2002 Aug;46(8):2700-3.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.